Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

BACKGROUND: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with poor prognosis of patients with ovarian cancer. AIM: In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuejiao, Chong, Yulong, Liu, Huize, Han, Yan, Niu, Mingshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465006/
https://www.ncbi.nlm.nih.gov/pubmed/26055813
http://dx.doi.org/10.1186/s13048-015-0166-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465006/
https://www.ncbi.nlm.nih.gov/pubmed/26055813
http://dx.doi.org/10.1186/s13048-015-0166-y

Ejemplares similares